Patterns of Variations in \u3ci\u3eEscherichia coli\u3c/i\u3e Strains That Produce
Cytolethal Distending Toxin by Pickett, Carol L. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Public Health Resources Public Health Resources 
2004 
Patterns of Variations in Escherichia coli Strains That Produce 
Cytolethal Distending Toxin 
Carol L. Pickett 
University of Kentucky, cpicket@uky.edu 
Robert B. Lee 
University of Kentucky 
Aysegul Eyigor 
University of Kentucky 
Ben Elitzur 
University of Kentucky 
Emily M. Fox 
University of Kentucky 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources 
 Part of the Public Health Commons 
Pickett, Carol L.; Lee, Robert B.; Eyigor, Aysegul; Elitzur, Ben; Fox, Emily M.; and Strockbine, Nancy A., 
"Patterns of Variations in Escherichia coli Strains That Produce Cytolethal Distending Toxin" (2004). 
Public Health Resources. 216. 
https://digitalcommons.unl.edu/publichealthresources/216 
This Article is brought to you for free and open access by the Public Health Resources at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by 
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Carol L. Pickett, Robert B. Lee, Aysegul Eyigor, Ben Elitzur, Emily M. Fox, and Nancy A. Strockbine 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/216 
INFECTION AND IMMUNITY, Feb. 2004, p. 684–690 Vol. 72, No. 2
0019-9567/04/$08.000 DOI: 10.1128/IAI.72.2.684–690.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Patterns of Variations in Escherichia coli Strains That Produce
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A collection of 20 Escherichia coli strains that produce cytolethal distending toxin (CDT) were analyzed for
their virulence-associated genes. All of these strains were serotyped, and multiplex PCR analysis was used to
ascertain the presence of genes encoding other virulence factors, including Shiga toxin, intimin, enterohemo-
lysin, cytotoxic necrotizing factor type 1 (CNF1) and CNF2, heat-stable toxin, and heat-labile toxin. These
CDT-producing strains possessed various combinations of known virulence genes, some of which have not been
noted before. Partial cdtB sequences were obtained from 10 of these strains, and their predicted CdtB se-
quences were compared to known E. coli CdtB sequences; some of the sequences were identical to known CdtB
sequences, but two were not. PCR primers based on sequence differences between the known cdt sequences were
tested for their ability to detect CDT producers and to determine CDT type. Correlations between the type of
CDT produced, the presence of other virulence properties, and overall strain relatedness revealed that the CDT
producers studied here can be divided into three general groups, with distinct differences in CDT type and in
their complement of virulence-associated genes.
The bacterial toxin cytolethal distending toxin (CDT) was
initially described as having the ability to cause certain cultured
cell lines to slowly distend and then die (18). More recently,
several groups have shown that CDT causes sensitive cells to
become apparently irreversibly blocked in either the G1 (6, 14)
or G2 phase of the cell cycle (4, 32, 36). CDT apparently
invokes this block by causing direct DNA damage through the
action of the CdtB protein, which is a member of a class of
phosphodiesterases that includes nucleases (8, 13, 19). The
CdtA and CdtC proteins appear to be required as accessory
proteins, mediating binding to the CDT receptor on sensitive
cells (20, 21). CdtA and CdtC may also possess additional
properties important for intoxication, but such roles have not
yet been defined (12).
CDT is produced by several different bacterial species, in-
cluding Escherichia coli, Shigella spp., Campylobacter jejuni and
related thermophilic campylobacters, Haemophilus ducreyi, Ac-
tinobacillus actinomycetemcomitans, and enterohepatic Helico-
bacter spp. (5, 18, 31, 35, 37). In all of these species, CDT
activity is encoded by three adjacent genes, cdtA, cdtB, and
cdtC, and the expression of all three genes is required for the
production of active CDT (31, 34). CDT production by E. coli
strains was first documented by Johnson and Lior (18), and the
cdt genes from three different E. coli strains were subsequently
cloned and sequenced (29, 30, 34). These sequence data indi-
cated that there is heterogeneity present in the E. coli cdt
genes. For example, the predicted amino acid sequences of
CdtA, -B, and -C from E. coli strains 9142-88 and 6468/62 have
48, 61, and 42% identical and conserved amino acids, respec-
tively (30, 34). The third strain sequenced, S5, is most closely
related to strain 9142-88, with CdtA, CdtB, and CdtC proteins
that have 93, 94, and 94% identical and conserved amino acids,
respectively (29). These CDTs have been called type I (strain
6468/62), type II (9142-88), and type III (strain S5), based on
the order of publication of their gene sequences (29).
In this report, we have examined cdt sequences from a va-
riety of E. coli strains in order to determine if additional se-
quence variants exist and to look for the possible association of
specific types of cdt sequence variants with different E. coli
virulence markers. Furthermore, we have tested the ability of
PCR methods to detect and distinguish between the CDT
types produced by these E. coli strains. Overall, our results
show that these CDT-producing strains can be divided into
three groups based upon their complement of virulence-asso-
ciated genes and their type of CDT. In addition, we show the
existence of two new E. coli CDT sequences that have not been
previously reported.
MATERIALS AND METHODS
Strains, medium, and growth. Twenty E. coli strains that carry cdt genes as
determined by PCR analysis (31) were used in this study. Nineteen of the strains
were isolated from humans; one, strain F5953-98, was isolated from a calf. All of
these strains but one were isolated from diverse geographical locations in the
United States and Canada over the last several years and include several different
serotypes (Table 1). Strain 3260-97 was originally isolated in Bangladesh. All of
the strains, with the exception of H1, H19, and 2P6, were sent to the Centers for
Disease Control and Prevention for serological or epidemiological analysis.
Strains H1, H19, and 2P6, blood culture isolates from adult humans with uro-
sepsis, were kindly provided by James R. Johnson and have been described by
Johnson and Stell (17). E. coli strain S5 was used as a control in some experi-
ments. It was kindly provided by Eric Oswald.
E. coli cultures were grown in L medium at 37°C at 250 rpm for 18 h. Strains
were tested for CDT production according to the methods of Pickett et al. (30,
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31). All 20 strains produced CDT titers between 30 and 200; any differences did
not correlate with CDT type, nor were they statistically significant.
PCR. An initial multiplex PCR analysis to determine the presence of diar-
rheagenic E. coli virulence genes was carried out as described previously (38).
This analysis detects the presence of the estI, eltI, stx1, stx2, eae, cnf1, Ehly, ipaH,
uidA, and bfpA genes and the EAF plasmid. Additional PCR tests were done to
analyze for the presence of cnf2, estII, and F17 fimbriae (2, 27, 28). eae subtypes
were determined by PCR analysis (1, 10, 22, 33).
PCR detection of cdt genes began with the use of the degenerative primers
VAT2 and WMI1, according to the method of Pickett et al. (31). These primers
are based on two highly conserved regions in cdtB and will amplify, in E. coli
strain 9142-88, a 510-nucleotide cdtB fragment encoding 170 amino acids (30,
31).
Additional PCR analysis of the cdt genes included use of the reactions de-
scribed by Okuda et al. (25) for detection of sequences related to the type I CDT
sequence found in E. coli strain 6468/62 (34) and the type II CDT sequence from
strain 9142-88 (30), as well as the PCR described by Clark et al. (3) for the
detection of type III CDT sequences, based on that found in E. coli strain S5
(29).
Our type I- and type II/III-specific PCR analysis of the cdtB gene described in
this work used four sequence-specific primers. Two of these primers were based
on the type I cdtB sequence, and two were based on the type II cdtB sequence
(30, 34). The type I primers were type I-F, 5-GCTTCTGCAACGTT(G,T)AC
TGAG-3, and type I-R, 5-AATCGCAAGATTTACTCTGTTAGCG-3, and
the type II primers were type II-F, 5-TCAACGGCTGTA(A,G)ATACAGG-3,
and type II-R, 5-CAGAGCAAGATTGACTCTTCCACCAAG-3. These for-
ward and reverse primers are based on amino acids 44 to 50 and 86 to 94 (Fig.
1), respectively. The forward primers were used in combination with the reverse
primer WMI1; the reverse primers were used in combination with the forward
primer VAT2. PCRs and cycle parameters were as described by Eyigor et al. (9),
except that the annealing temperature was 47°C. All PCR primers were synthe-
sized by Integrated DNA Technologies (Coralville, Iowa).
Randomly amplified polymorphic DNA (RAPD) PCR was performed using
the Ready-to-Go RAPD analysis kit according to the manufacturer’s instructions
(Amersham Pharmacia Biotech, Piscataway, N.J.). All six primers from this kit as
well as primers 1247 and 1281 used for analysis of E. coli strains by Madico et al.
(23) were tested for use in these studies. Primers 1, 2, and 3 from the Ready-
to-Go kit proved to give the best range and distribution of product sizes.
FIG. 1. Alignment of partial CdtB sequences. A comparison of the sequences of a portion of the predicted sequence of CdtB from five E. coli
isolates is shown. The names of the strains are shown at the left. Strain 3032-96 makes a type III CDT, strains 3260-97, 3102-97, and 9142-88 make
a type II CDT, and strain 3015-99 makes a type I CDT. The amino acid sequences are numbered continuously at the right. The initial valine shown
is residue number 25 of the CdtB sequence of E. coli strain 9142-88 (30).
TABLE 1. E. coli strains used in this study and their
relevant characteristics
Strain Oa Hb CDTc stx1d stx2d eaee Ehlyf cnf1g cnf2h
9142-88 128 NM II      
3102-97 R NM II      
3260-97 R NM II      
3032-96 119 NM III      
F6450-99 119 4 III      
3139-97 88 25 III      
3180-98 U 45 I      
3015-99 2 NM I      
3061-99 18 1 I      
H1 2 1 I      
H19 2 NM I      
2P6 2 7 I      
3008-99 2 NM I      
3142-98 63 4 I      
3148-97 113 21 II/III      
3084-98 158 NM IIi      
F5953-98 126 8 IIIj      
3014-99 88 7 II/III      
F5971-99 U 25 II/III      
F6448-99 73 18 II/III      
a O antigen serogroup of the indicated E. coli strain. R, rough O antigen; U,
O serogroup could not be determined with available reference sera.
b H antigen. NM, nonmotile.
c CDT type. II/III, strains could not be reliably designated as II or III since
their cdtB genes were not sequenced.
d Shiga toxin gene, based on primers described by Olsvik et al. (26).
e Intimin gene; for eae and eae subtype determination, see references 1, 10, 22,
and 33. Strains 3102-97 and 3084-98 were determined to be eae, but no eae
subtype assignment could be made for 9142-88 or 3260-97.
f Enterohemolysin; primers were described in Fratamico et al. (11).
g Cytotoxic necrotizing factor type I gene, as reported in Johnson and Stell (17).
h Cytotoxic necrotizing factor type 2 gene; primers were described in Pass et al.
(28).
i 3084-98 was designated type II on the basis of type-specific PCR only (see text
and references 3 and 25).
j F5953-98 was designated type III solely on the basis of type-specific PCR (3).
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Cloning and sequencing. Total DNA was isolated from E. coli strains using a
QIAamp tissue kit (Qiagen Inc., Valencia, Calif.), after which the TOPO TA
cloning kit (Invitrogen Corp., Carlsbad, Calif.) was used to amplify and clone a
portion of the selected strain’s cdtB gene. The degenerative sequences, VAT2
and WMI1, described above were used as primers in the amplification. At least
two clones originating from each strain were sequenced (SeqWright, Houston,
Tex.).
Nucleotide sequence accession numbers. The nucleotide sequences of the
partial cdtB genes have been assigned GenBank accession numbers AY423896,
AY423897, AY426340, and AY426341.
RESULTS
Analysis of cdtB sequences revealed invariant and variant
CDT types. Multiplex PCR analysis for virulence factors com-
monly associated with E. coli disease indicated that E. coli
strains identified as carrying the cdt genes apparently often
carry additional virulence markers associated with either diar-
rheagenic or uropathogenic E. coli (Table 1). Based on these
data, a portion of the sequence of the cdtB gene from 10
representative strains was amplified, cloned, and sequenced for
comparison to already-known E. coli cdtB sequences. Transla-
tions of the partial sequences of five strains’ cdtB genes are
presented in Fig. 1. Strain 3032-96, whose complete amino acid
sequence for the cloned region is shown, has a sequence that is
identical to that of the type III CDT-producing strain, S5 (29).
Two other strains, F6450-99 and 3139-97, also had this same
sequence (data not shown). Another two strains, 3260-97 and
3102-88, had sequences similar to the S5 sequence and to the
type II CDT-producing strain, 9142-88, (30), but several amino
acid substitutions were present in the sequences in each of
these strains (Fig. 1). The figure compares these substitutions
to the sequences for both S5 and 9142-88; overall, the four
sequences vary at 12 different residues within the 165-amino-
acid cdtB fragment shown. Finally, strain 3015-99 represented
five strains with identity to the type I strain, 6468/62, whose cdt
gene sequence was reported by Scott and Kaper (34). One of
these five strains, 3180-98, had a single amino acid substitution,
Gly for Arg, at position 89. Overall, our results indicated the
presence of three types of sequences that could be grouped
into two broad divisions. First, there were those sequences that
were identical or nearly identical to the type I sequence re-
ported by Scott and Kaper (34). Secondly, there was a group of
strains with partial CdtB sequences identical to that found in
the type III CDT strain S5 (29). And lastly, there were two
strains with partial CdtB sequences that were closely similar to
that of both the type II strain 9142-88 (30) and the type III
strain S5 (29) but which had at least five substitutions within
the 165-amino-acid region of CdtB when compared to the
prototype type II and III strains (Fig. 1). When referring to the
latter two groups together, we have called them the typeII/III
group. Individually, type II strains include the prototype type II
strain 9142-88 as well as the two strains 3260-97 and 3102-97
that were similar but not identical to both 9142-88 and S5.
Type III strains are those strains whose sequences were iden-
tical to that of S5.
Type-specific PCR for classification of cdt genes. Examina-
tion of the different partial cdtB sequences suggested that it
would be possible to make PCR primers that were specific for
either type I or for type II and III (II/III) cdtB sequences. We
used four specific primers in combination with VAT2 or WMI1
to test whether we could use these primers in a screening PCR
to determine if an E. coli strain likely had a type I or type II/III
cdtB gene. We first tested the primers with several strains for
which the sequence in the relevant region had already been
determined. In every case, the type I primers, in combination
with VAT2 or WMI1 (Table 2), amplified only sequences of
the expected sizes from type I strains. Figure 2 shows the
results for two known type I strains, 3061-99 and 3015-99. A
PCR product was produced with only one of the two primer
sets for each strain. For example, type I strain 3061-99 yielded
a product with the type I primers (lane 2), but not with the type
II/III primer set (lane 8). Similarly, the type II/III primers only
amplified sequences of the expected sizes from known type II
or type III strains (Table 1; Fig. 2, lane 11; and data not
shown). We then tested the primer sets on eight additional
CDT producers whose cdtB gene had not been sequenced. Of
these strains, two produced a product with the type I primers
(Table 2; Fig. 2, lanes 3 and 7) and the remaining six strains
produced a PCR product only when tested with the type II/III
primers (Table 2 and Fig. 2, lane 10, for strain 3084-98). All of
the strains acted in a consistent and reproducible manner,
FIG. 2. PCR products showing CDT type specificity. Primers for
lanes 2 to 7 were type I-1R and VAT-2. Primers for lanes 8 to 13 were
type II-1F and WMI-1. Lanes: 1 and 14, HaeIII X174; 2 and 8,
3061-99; 3 and 9, 3142-98; 4 and 10, 3084-98; 5 and 11, 3260-97; 6 and
12, 3015-99; 7 and 13, 3008-99. Selected DNA fragment standard sizes,
in base pairs, are shown to the right.
TABLE 2. CDT type-specific PCR of E. coli strainsa
Strain
PCR
Sequenceb
Type I-F Type II-F Type I-R Type II-R
6468/62     Type I
3180-98     Type I
3015-99     Type I
3061-99     Type I
2P6     Type I
H19     Type I
3142-98     NS
3008-99     NS
9142-88     Type II
3032-96     Type III
3260-97     Type II
F6450-99     Type III
3148-97     NS
3084-98     NS
F5953-98     NS
3014-99     NS
F5971-99     NS
F6448-99     NS
a Four different sets of PCR primers were used: type I-F and WMI-1, type II-F
and WMI-1, type I-R and VAT-2, and type II-R and VAT-2.
b Type I strains have partial CdtB sequences identical to that of strain 6468/62
(34). Type II strains have partial CdtB sequences identical or closely similar to
that of 9142-88 (30), and type III strains have partial CdtB sequences identical or
nearly identical to that of strain S5 (29). NS, not sequenced.
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suggesting that these type-specific primers can be successfully
used to differentiate type I from type II and type III CDT-
producing strains. These primers cannot distinguish between
type II and type III sequences.
Clark et al. (3) recently reported on the use of three sets of
PCR primers for distinguishing between the three types of cdt
genes. The PCR primers for detection and amplification of the
type I and type II cdt genes were first reported by Okuda et al.
(25) and are derived from the cdtA genes of the type I and type
II prototype strains, 6468/62 and 9142-88, respectively. The
type III primers are taken from the cdtA and cdtC genes of S5,
such that the entire cdt coding region is amplified (3, 29). We
tested these primers on our CDT-producing strains in order to
determine if they would successfully detect and distinguish the
different cdt sequences in these strains. The best results were
achieved with the type I primers, although these were not
without deficiencies. The type I strains 3008-99, 3015-99, 3061-
99, H1, H19, and 2P6 all produced a single appropriately sized
product (575 bp) with the type I primers. The results for type
I strains 2P6, 3008-99, 3015-99, and 3061-99 are shown in Fig.
3A. However, type I strain 3180-98 produced no PCR product,
and type I strain 3142-98 produced only a trace amount of
product with these primers (Fig. 3A, lanes 9 and 8, respec-
tively). No type II or type III cdt sequences were amplified by
these primers.
The type II and type III reactions had additional problems.
As expected, the type II primers successfully amplified the
appropriate region of cdtA from 9142-88 (Fig. 3B, lane 11). In
addition, these type II primers also produced a significant
amount of amplified product from strains 3084-9 and 3102-97
(Fig. 3B, lanes 6 and 10). The type III primers amplified the cdt
genes from strains F5953-98, F6450-99, and 3032-96 (Fig. 3C,
lanes 5, 8, and 9) as well as from the prototype strain, S5 (lane
1). These results for both the type II and type III primers are
in agreement with our sequencing results for strains 3102-97,
3032-96, and F6450-99; no cdt genes from strains F5953-98 and
3084-98 have been sequenced. However, neither the type II
nor type III primers could amplify any product from the type
II/III strain 3014-99 (Fig. 3B, lane 2, and data not shown).
Similarly, the type II primers produced only faint products and
the type III primers produced no products with the type II/III
strains 3148-97, F5971-99, and F6448-99 (Fig. 3B and C). The
faint products that these latter three strains produced, as well
as the product produced from the known type II strain 3260-97,
with the type II primers were less distinct than the product
produced from strain S5, the prototype type III strain (Fig. 3B,
compare lane 1 to lanes 3, 4, 7, and 9). Strain 3139-97, a known
type III strain, produced no product with the type III primers
(Fig. 3C, lane 7). In other words, 6 of the 12 type II or type III
strains either were undetected by these primers or, in the case
of some results with the type II primers, the amplified products
appeared to be the result of non-type-specific amplification,
since the amount of product was less than that produced by the
type III control strain. These results indicated that the type
II-specific primers are not specific and will amplify cdt se-
quences in some type III strains and that some type II and type
III strains are not detected by either the type II or type III
primers.
Correlation of strain characteristics and CDT type. Analysis
of the strains’ known virulence factors and serotypes in relation
to CDT type revealed some interesting associations (Table 1).
Of the eight strains identified as encoding type I CDT, five
were serogroup O2 and, of these, three were O2 nonmotile
strains. Three of the strains, H1, H19, and 2P6, were initially
identified as CDT producers in a study by Johnson and Stell
(17) of E. coli strains associated with urosepsis, and certain O2
serotypes are well documented to be relatively common causes
of this type of extraintestinal infection. However, the other two
O2 strains with a type I CDT were also not stool isolates;
3008-99 was isolated from the urine of a 77-year-old female,
and strain 3015-99 was isolated from the blood of a 40-year-old
female. The other three type I strains, 3180-98, 3061-99, and
3142-98, were all isolated from human stools but, in common
with the O2 serogroup type I strains, they did not encode Shiga
FIG. 3. PCR products produced by type I, type II, or type III
CDT-producing strains. (A) PCR products amplified from the indi-
cated E. coli strains with the type I-specific primers of Okuda et al.
(25). Lanes: 1, 3014-99; 2, 3139-97; 3, F6450-99; 4, 2P6; 5, 3008-99; 6,
3015-99; 7, 3061-99; 8, 3142-98; 9, 3180-98; 10, 123-bp ladder. (B) PCR
products amplified from E. coli strains with the type II-specific primers
of Okuda et al. (25). Lanes: 1, S5; 2, 3014-99; 3, F5971-99; 4, F6448-99;
5, F5953-98; 6, 3084-98; 7, 3148-97; 8, 3032-96; 9, 3260-97; 10, 3102-97;
11, 9142-88; 12, 123-bp ladder. (C) PCR products amplified from E.
coli strains with the type III-specific primers of Clark et al. (3). Lanes:
1, S5; 2, 9142-88; 3, F5971-99; 4, F6448-99; 5, F5953-98; 6, 3148-97; 7,
3139-97; 8, F6450-99; 9, 3032-96; 10, 123-bp ladder. (D) PCR products
amplified from E. coli strains with CNF2-specific primers. Lanes: 1, S5;
2, 9142-88; 3, F5971-99; 4, F6448-99; 5, F5953-98; 6, 3148-97; 7, 3139-
97; 8, F6450-99; 9, 3032-96; 10, 123-bp ladder. Sizes of relevant base
pair markers are at the right.
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toxin, enterohemolysin, or intimin. However, only the O2 se-
rogroup type I strains possessed pap genes as assessed by PCR
(reference 17 and data not shown). These results do not show
that all CDT type I strains form a distinct clone, but they do
indicate that at least a subset of type I CDT-producing strains
appear to be associated with E. coli extraintestinal infections
and that serogroup O2 strains that produce CDT likely possess
type I CDT genes. In general, type I CDT-producing strains
share the distinction of not having any of several known E. coli
diarrheagenic-associated virulence markers (Table 1).
The type II CDT-producing strains varied from the type III
strains based both on their cdtB fragment sequence and upon
their complement of known virulence markers. There were
three type III strains that encoded Stx1 and CNF2 but not
intimin (Table 1; Fig. 3D); these are the same three strains that
produced a product with the type III primers based on the cdt
sequences in strain S5 (Fig. 3C). These strains appear to be
similar to some of the bovine strains described by De Rycke et
al. (7) in that they encode CDT type III and CNF2 but not F17
fimbriae (data not shown), although two of these three strains
were isolated from humans. In any case, these strains appear to
define a group of similar CDT-producing strains that make a
type III CDT and also produce CNF2 and Stx1. The other
known type III strain, 3139-97, encoded Stx1, Stx2, and the
enterohemolysin. This strain was not identified by the type
III-specific primers of Clark et al. (3) and thus appears to be
distinct from the already-mentioned group of type III strains.
The three sequence-verified type II strains encode intimin,
but apparently they encode no known E. coli toxins other than
CDT (Table 1). In addition, one of the nonsequenced type
II/III strains was identified as type II on the basis of a type
II-specific PCR. This strain, 3084-98, also possesses an eae
gene but none of the other virulence genes tested for in this
work. None of these eae-carrying type II CDT producers tested
positive for the presence of the EAF plasmid and, of note, all
were nonmotile. These four strains appear to constitute an-
other group of strains with significant commonalities, although
their pathogenic significance is presently unknown. However,
one of these CDT type II strains, 3260-97, is one of five strains
that were described previously by Janda et al. (15) as either
unusual biotypes of E. coli or as representatives of a new
Escherichia species. All five of these strains were isolated from
humans with diarrheal disease, and all five produce CDT (data
not shown).
In addition to the six type II or III strains for which partial
cdtB sequence data were obtained, six additional type II or III
strains are shown in Table 1. Two of these strains, 3084-98 and
F5953-98, were identified as to their CDT type based on the
type II- and III-specific PCR methods discussed above (3). The
other four strains have not yet been conclusively identified as
to their CDT type, other than that they belong to either type II
or type III (Tables 1 and 2). Three of these strains encode Stx2,
and one of these also encodes Stx1. Our results from the
sequenced strains would suggest that these strains are likely
type III strains. The fourth strain identified as carrying either
type II or III cdt genes, 3014-99, encoded neither intimin nor
any toxins other than CDT in repeated PCR tests.
RAPD analysis. In an effort to learn more about the possible
relatedness of strain 3014-99 to selected representatives of the
different CDT types, RAPD analysis was performed. Each
strain listed in Table 1 as well as some known siblings of
selected strains were tested. These experiments are continuing,
but our results, some of which are shown in Fig. 4, indicated
that strain 3014-99, which has a type II/III partial cdtB se-
quence based on type-specific PCR, had a primer 2 RAPD
pattern identical to that of several type I strains, including
3061-99, 3008-99, and 3015-99 (Fig. 4, lanes 5, 6, 7, and 8). The
3014-99 patterns achieved with primers 1 and 3 also appeared
to be closely similar to that of the type I group, including strain
3008-99 (data not shown).
DISCUSSION
These studies were initiated in order to discover more about
the relatedness of CDT-producing E. coli strains. The strains
examined here were recovered from both gastrointestinal and
extraintestinal infections. Partial sequence information derived
from these strains indicated that cdt sequences can be broken
down into two general categories: type I and type II/III. The
type I strains studied here have CdtB partial sequences that are
identical or nearly identical to that of strain E6468/62 reported
by Scott and Kaper (34). The type II/III strains have CdtB
partial sequences that are similar or identical to that of the
type II and type III prototype strains 9142-88 and S5 (29, 30).
We have grouped the type II and type III strains together
because the cdt sequences of the prototype strains are closely
related to each other (93 to 94% identical and conserved
amino acids for all three Cdt subunits).
Overall, our isolates included several strains with CdtB par-
tial sequences that were identical to the prototype type I and
type III sequences, but two strains possessed CdtB sequences
closely related, but not identical, to the type II and III se-
quences of both S5 and 9142-88. We have chosen not to assign
these strains separate types (e.g., types IV and V) but rather to
call them variants of the type II/III group, since their cdt genes
have not been sequenced in their entirety and because it is not
known if the Cdt proteins produced by these strains differ
significantly in their antigenic specificities or in any other way.
It is possible that there are other substantially different types
of E. coli cdt sequences, but the use of the degenerative prim-
ers VAT2 and WMI1 for our initial screen for the presence of
FIG. 4. RAPD analysis of CDT-producing E. coli strains, with an
agarose gel (1%) of DNA fragments produced by RAPD using primer
2 and template DNA from the indicated strains. Lanes 1 and 12,
123-bp ladder (Invitrogen Corp.); lane 2, 3142-98 (type I); lane 3,
3180-98 (type I); lane 4, 3179-98 (a sibling of 3180-98); lane 5, 3061-99
(type I); lane 6, 3015-99; lane 7, 3008-99 (type I); lane 8, 3014-99 (type
II/III); lane 9, F5971-99 (type II/III); lane 10, F5953-98 (type III); lane
11, 3139-97 (type III). The lowest rung of the 123-bp ladder is indi-
cated at the right.
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cdt sequences was chosen in order to detect as many variants as
possible. These primers are derived from regions of CdtB that
are very highly conserved in all CdtBs and have been used to
detect cdt sequences in several different genera (e.g., refer-
ences 6 and 26).
While sequence data suggested two general groups of CDT
producers, analysis of the strains’ complements of virulence
markers suggested that there were really at least three basic
types of CDT producers. The type I CDT-producing strains
analyzed here produced no other toxins besides CDT, with the
exception of one strain that encoded cytotoxic necrotizing fac-
tor type 1 (CNF1). Several of the type I CDT strains were
serogroup O2 and all of these possessed pap genes, indicating
that these strains probably belong to the well-studied O2 group
of extraintestinal (uropathogenic) strains. The other type I
strains did not possess pap genes, and more study will be
needed to determine whether these strains have a similar
pathogenic potential.
Type II/III strains seemed to fall into two classes: those that
make intimin but not any known toxins other than CDT, and
those that make one or more Shiga toxins. Interestingly, the
latter group included the three strains 3032-96, F6450-99, and
3139-97 whose partial CdtB sequences were identical to that of
S5. PCR tests for other virulence markers indicated that the
unsequenced strains F5953-98, 3148-97, F5971-99, and F6448-
99 also belong to this group of strains that encode Shiga toxin.
Three of these seven Shiga toxin-producing strains also en-
coded CNF2, suggesting a relationship with the CNF2 produc-
ers profiled by De Rycke et al. (7). However, only one of our
CNF2-producing strains, F5953-98, was a bovine isolate, sug-
gesting that at least some type III CDT-producing, CNF2-
producing E. coli strains can affect humans.
On the other hand, the strains that encode intimin and CDT
included 9142-88, the prototype type II strain, and the two
strains, 3102-97 and 3260-97, that possessed the new variant
CdtB sequences shown here (Fig. 1). In addition, strain
3084-98 can be included in this group since it encodes intimin
and CDT, and it was identified as a type II strain by type-
specific PCR (Fig. 3B). These strains, which we are calling type
II strains, appear to form a group of CDT producers that
possess similar virulence markers and that have related, but
not necessarily identical, cdt sequences. The pathogenic poten-
tial of this group is unclear, but their identification as a subset
of CDT producers should facilitate future studies aimed at
determining CDT’s role in E. coli disease.
On the genetic level, the variation seen in the type II strains’
cdt sequences may reflect accumulated changes since acquisi-
tion of ancestral cdt genes, or it may mean that multiple trans-
fers of closely related but nonidentical cdt sequences have
occurred within this group of Eae-producing strains. The
former seems a more likely hypothesis, given the similar com-
plement of virulence-associated genes present in these strains.
On the other hand, the cdt sequence identity found in the type
III strains may argue for more recent acquisition of the cdt
genes by these Shiga toxin-producing strains.
Strain 3014-99 presents an interesting exception to the gen-
eral correlations described for the type I, II, and III strains.
Based on PCR tests, this strain produces type II or III CDT,
yet the overall genetic make-up of the strain, reflected in
RAPD analysis, and also its lack of genes encoding either
Shiga toxin or intimin appear to indicate that it is more closely
related to type I CDT-producing E. coli than to the type II or
III CDT producers. It will be of interest to further characterize
both this strain as well as additional strains in related groups so
that we can better understand the genetics, biology, and patho-
genic potential of E. coli CDT-producing strains.
While preparing this report, a paper appeared by Clark et al.
(3) which looked at the association of cdt genes with other
virulence markers from selected groups of E. coli strains iso-
lated from both animals and humans. Their results were some-
what similar to our correlations, but not identical. For exam-
ple, they found that many type I-producing E. coli strains
possessed no other known virulence markers, except that sev-
eral type I strains also produced CNF1. They found that type
III CDT producers were most often combined with either
CNF2 or CNF2 and Stx1. These strains were generally derived
from cattle, and thus the association with CNF2 and Stx1 is not
surprising. Our greatest difference was in characterization of
the type II and III strains. Our type II strains all contained eae
genes, while only one of five of theirs did and it was in com-
bination with cnf1. Also, two of our type III strains contained
both stx1 and stx2 genes, while none of theirs did. In fact, only
2 of their 50 CDT producers contained an stx2 gene, while four
out of seven of our type III strains had an stx2 gene. It should
also be noted that their method of distinguishing the type of
CDT differed from our methods. They used PCR primers
based primarily on differences within the cdtA gene of the
three prototype strains (18). In agreement with our studies of
the cdtB gene from type III strains reported here, their type III
sequences were identical to that of strain S5. (The cdt PCR
products from type I and type II strains produced by these
investigators based on sequences from strains 6468/62 and
9142-88, respectively, were not sequenced.) However, our data
clearly indicate that sequences within the type II group can
vary, and our use of their primers with our strains showed that,
in fact, these primers did not detect or distinguish all CDT
producers within the three CDT type groups. This in turn
suggests that additional, as-yet-unsequenced variations exist
and that use of degenerative primers for preliminary screening
for CDT producers is warranted.
Our RAPD and sequence data support the notion that
strains that produce a particular type of CDT may be more
closely related to each other than to other E. coli CDT pro-
ducers but that not all strains producing a particular type of
CDT can be considered close relatives (e.g., type 1 strains
3008-99 and 3180-98). That is, strains that produce a particular
type of CDT may comprise two or more clonal groups of E. coli
pathogens. Our RAPD data also suggest that some of the E.
coli CDT-producing strains, such as the type I strains 3008-99
and 3061-99, may be closely related to each other despite
having different serotypes.
The results presented here are an attempt to begin defining
what types of E. coli pathogens produce CDT. Our data indi-
cate that a fairly defined subset of uropathogenic E. coli strains
contain cdt genes, that additional extraintestinal isolates of
uncertain clonal identity also can carry cdt genes, and that
strains with at least some characteristics in common with Shiga
toxin-producing E. coli and enteropathogenic strains can carry
cdt genes. A recent report by Janka et al. (16) indicated that
O157:H strains and, rarely, O157:H7 strains may encode a
VOL. 72, 2004 CYTOLETHAL DISTENDING TOXIN-PRODUCING E. COLI STRAINS 689
type III-like CDT. In addition, Mainil et al. (24) recently de-
scribed a variant of type I CDT which they termed type IV
CDT and which was found in some CNF1-producing E. coli
strains from a variety of sources. Additional combinations of
E. coli virulence genes among CDT producers appear likely to
exist given the variation seen here and that reported by others.
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